MicroRNAs as new characters in the plot between epigenetics and prostate cancer

Frontiers in Genetics

Volumn 2, Issue SEP, 2011, Pages

  Paone, Alessio ^a   Galli, Roberta ^a   Fabbri, Muller ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Epigenetics; Histone acetylation; Methylation; MicroRNA; Prostate cancer; Rogen receptor

Indexed keywords

EID: 84872270053     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2011.00062     Document Type: Article

References (55)

1. Ambros, V. (2001). microRNAs: tiny regulators with great potential. Cell 107, 823-826.
2. Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116,281-297.
3. Cao, P., Deng, Z., Wan, M., Huang, W., Cramer, S. D., Xu, J., Lei, M., and Sui, G. (2010). MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by andro-gen receptor and HIF-1alpha/HIF-1beta. Mol. Cancer 9, 108.
4. Coolen, M. W., Stirzaker, C., Song, J. Z., Statham, A. L., Kassir, Z., Moreno, C. S., Young, A. N., Varma, V., Speed, T. P., Cowley, M., Lacaze, P., Kaplan, W., Robinson, M. D., and Clark, S. J. (2010). Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcrip-tional plasticity. Nat. Cell Biol. 12, 235-246.
5. Croce, C. M. (2009). Causes and consequences of microRNA dysregula-tion in cancer. Nat. Rev. Genet. 10, 704-714.
6. Dillhoff, M., Wojcik, S. E., and Bloom-ston, M. (2008). MicroRNAs in Solid Tumors. J. Surg. Res. 154, 349-354.
7. Fabbri,M. (2008). MicroRNAs and cancer epigenetics. Curr. Opin. Investig. Drugs 9, 583-590.
8. Fabbri, M., and Croce, C. M. (2011). Role of microRNAs in lymphoid biology and disease. Curr. Opin. Hematol. 18,266-272.
9. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S., Guler, G., Morrison, C. D., Chan, K. K., Marcucci, G., Calin, G. A., Hueb-ner, K., and Croce, C. M. (2007a).MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805-15810.
10. Fabbri, M., Ivan, M., Cimmino, A., Negrini, M., and Calin, G. A. (2007b). Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin. Biol. Ther. 7, 1009-1019.
11. Folini, M., Gandellini, P., Longoni, N., Profumo, V., Callari, M., Pennati, M., Colecchia, M., Supino, R., Ven-eroni, S., Salvioni, R., Valdagni, R., Daidone, M. G., and Zaffaroni, N. (2010). MiR-21: an oncomir on strike in prostate cancer. Mol. Cancer 9, 12.
12. Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., Deguchi, T., and Ito, M. (2008). Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 377, 114-119.
13. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., Havelange, V., Volinia, S., Blum, W., Rush, L. J., Perrotti, D., Andreeff, M., Bloomfield, C. D., Byrd, J. C., Chan, K., Wu, L. C., Croce, C. M., and Marcucci, G. (2009). MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113,6411-6418.
14. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., and Goodall, G. J. (2008). The miR-200family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10,593-601.
15. Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., and Rob-son, C. N. (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59,177-189.
16. Heinlein, C. A., and Chang, C. (2004). Androgen receptor in prostate cancer. Endocr. Rev. 25,276-308.
17. Hermeking, H. (2007). p53 enters the microRNA world. Cancer Cell 12, 414-418.
18. Hulf, T., Sibbritt, T., Wiklund, E. D., Bert, S., Strbenac, D., Statham, A. L., Robinson, M. D., and Clark, S. J. (2011). Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics 12, 54. doi: 10.1186/1471-2164-12-54
19. Jarrard, D. F., Kinoshita, H., Shi, Y., Sandefur, C., Hoff, D., Meisner, L. F., Chang, C., Herman, J. G., and Isaacs, W. B. (1998). Nassif N Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58, 5310-5314.
20. Kinoshita, H., Shi, Y., Sandefur, C., Meisner, L. F., Chang, C., Choon, A., Reznikoff, C. R., Bova, G. S., Friedl, A., and Jarrard, D. F. (2000). Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60, 3623-3630.
21. Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., and Ito, M. (2010). MiR-34a attenuates paclitaxel-resistance of hormone-refractoryprostate cancer PC3 cells through direct and indirect mechanisms. Prostate70, 1501-1512.
22. Kong, D., Li, Y., Wang, Z., Banerjee, S., Ahmad, A., Kim, H. R., and Sarkar, F. H. (2009). MiR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27, 1712-1721.
23. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoha-ran, M., and Stoffel, M. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
24. Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120,15-20.
25. Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., Wiggins, J. F., Bader, A. G., Fagin, R., Brown, D., and Tang, D. G. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat.Med. 17,211-215.
26. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., and Hermeking, H. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7,2591-2600.
27. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., Downing, J. R., Jacks, T., Horvitz, H. R., and Golub, T. R. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838
28. Nakayama, T., Watanabe, M., Suzuki, H., Toyota, M., Sekita, N., Hirokawa, Y., Mizokami, A., Ito, H., Yatani, R., and Shiraishi, T. (2000). Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Invest. 80, 1789-1796.
29. Narayanan, R., Jiang, J., Gusev, Y., Jones, A., Kearbey, J. D., Miller, D. D., Schmittgen, T. D., and Dalton, J. T. (2010). MicroRNAs are mediators of androgen action in prostate and muscle. PLoS ONE 5, e13637. doi: 10.1371/journal.pone.0013637
30. Noonan, E. J., Place, R. F., Pookot, D., Basak, S., Whitson, J. M., Hirata, H., Giardina, C., and Dahiya, R. (2009). MiR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28, 1714-1724.
31. Ostling, P., Leivonen, S. K., Aakula, A., Kohonen, P., Mäkelä, R., Hag-man, Z., Edsjö, A., Kangaspeska, S., Edgren, H., Nicorici, D., Bjartell, A., Ceder, Y., Perälä, M., and Kallion-iemi, O. (2011). Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 71, 1956-1967.
32. Patra, S. K., Patra, A., and Dahiya, R. (2001). Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem. Biophys. Res. Commun. 287,705-713.
33. Rauhala, H. E., Jalava, S. E., Isotalo, J., Bracken, H., Lehmusvaara, S., Tam-mela, T. L., Oja, H., and Visakorpi, T. (2010). MiR-193b is an epige-netically regulated putative tumor suppressor in prostate cancer. Int. J. Cancer 127, 1363-1372.
34. Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., and Oren, M. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26,731-743.
35. Reibenwein, J., Pils, D., Horak, P., Tomicek, B., Goldner, G., Worel, N., Elandt, K., and Krainer, M. (2007). Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67, 427-432.
36. Ribas, J., and Lupold, S. E. (2010). The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 9, 923-929
37. Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasub-ramanian, S., Luo, J., Rodriguez, R., Mendell, J. T., and Lupold, S. E. (2009). MiR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 69, 7165-7169.
38. Rokhlin, O. W., Scheinker, V. S., Taghiyev, A. F., Bumcrot, D., Glover, R. A., and Cohen, M. B. (2008). MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol. Ther. 7, 1288-1296.
39. Saito, Y., Friedman, J. M., Chihara, Y., Egger, G., Chuang, J. C., and Liang, G. (2009). Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 379,726-731.
40. Sasaki, M., Tanaka, Y., Perinchery, G., Dharia, A., Kotcherguina, I., Fuji-moto, S., and Dahiya, R. (2002). Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J. Natl. Cancer Inst. 94, 384-390.
41. Schotte, D., Lange-Turenhout, E. A., Stumpel, D. J., Stam, R. W., Buijs-Gladdines, J. G., Meijerink, J. P., Pieters, R., and Den Boer, M. L. (2010). Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lym-phoblastic leukemia. Haematologica 95,1675-1682.
42. Shen,M.M.,andAbate-Shen,C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000.
43. Shi, G. H., Ye, D. W., Yao, X. D., Zhang, S. L., Dai, B., Zhang, H. L., Shen, Y J., Zhu, Y., Zhu, Y P., Xiao, W. J., and Ma, C. G. (2010). Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol. Sin. 31,867-873.
44. Sikand, K., Slaibi, J. E., Singh, R., Slane, S. D., and Shukla, G. C. (2010). MiR 488 inhibits androgen receptor expression in prostate carcinoma cells. Int. I Cancer. 129,810-819
45. Tsai, K. W., Hu, L. Y., Wu, C. W., Li, S. C., Lai, C. H., Kao, H. W., Fang, W. L., and Lin, W. C. (2010). Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer 49, 969-980.
46. Varambally, S., Cao, Q., Mani, R. S., Shankar, S.,Wang, X.,Ateeq, B., Lax-man, B., Cao, X., Jing, X., Ram-narayanan, K., Brenner, J. C., Yu, J., Kim, J. H., Han, B., Tan, P., Kumar-Sinha, C., Lonigro, R. J., Palanisamy, N., Maher, C. A., and Chinnaiyan, A. M. (2008). Genomic loss of microRNA-101 leads to over-expression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699.
47. Vasudevan, S., Tong, Y., and Steitz, J. A. (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science 318, 1931-1934.
48. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Fer-racin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce, C. M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261.
49. Waltering, K. K., Porkka, K. P., Jalava, S. E., Urbanucci, A., Kohonen, P. J., Latonen, L. M., Kallioniemi, O. P., Jenster, G., and Visakorpi, T. (2010). Androgen regulation of micro-RNAs in prostate cancer. Prostate 71, 604-614.
50. Weichert, W., Röske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., and Kris-tiansen, G. (2008). Histone deacety-lases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98, 604-610.
51. Yaman Agaoglu, F., Kovancilar, M., Diz-dar, Y., Darendeliler, E., Holden-rieder, S., Dalay, N., and Gezer, U. (2011). Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 32, 583-588
52. Yamanaka, M., Watanabe, M., Yamada, Y., Takagi, A., Murata, T., Takahashi, H., Suzuki, H., Ito, H., Tsukino, H., Katoh, T., Sugimura, Y., and Shiraishi, T. (2003). Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer 106, 382-387.
53. Zaman, M. S., Chen, Y., Deng, G., Shahryari, V., Suh, S. O., Saini, S., Majid, S., Liu, J., Khatri, G., Tanaka, Y., and Dahiya, R. (2010). The functional significance of microRNA-145 in prostate cancer. Br. J. Cancer 103, 256-264.
54. Zhang, H. L., Yang, L. F., Zhu, Y., Yao, X. D., Zhang, S. L., Dai, B., Zhu, Y P., Shen, Y J., Shi, G. H., and Ye, D. W. (2011). Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71, 326-331.
55. Zhao, S., Wang, Y., Liang, Y., Zhao, M., Long, H., Ding, S., Yin, H., and Lu, Q. (2011). MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 63, 1376-1386.